Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis

Journal of Infection

Volumn 63, Issue 5, 2011, Pages 344-350

  Savva, Athina ^a   Raftogiannis, Maria ^a   Baziaka, Fotini ^a   Routsi, Christina ^b   Antonopoulou, Anastasia ^a   Koutoukas, Pantelis ^a   Tsaganos, Thomas ^a   Kotanidou, Anastasia ^b   Apostolidou, Efterpi ^c   Giamarellos Bourboulis, Evangelos J ^a   Dimopoulos, George ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Ptolemaida General Hospital   (Greece)

Author keywords

Procalcitonin; Prognosis; Sepsis; Severity; SuPAR

Indexed keywords

PROLACTIN; UROKINASE RECEPTOR;

ADULT; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; MONOCYTE; NEUTROPHIL; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROGNOSIS; PROLACTIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; SEPSIS; SEPTIC SHOCK; VENTILATOR ASSOCIATED PNEUMONIA;

ADULT; APACHE; BIOLOGICAL MARKERS; CALCITONIN; COHORT STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEUTROPHILS; PNEUMONIA, VENTILATOR-ASSOCIATED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; SEPSIS; SEVERITY OF ILLNESS INDEX; SOLUBILITY; YOUNG ADULT;

EID: 80054074744     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.07.016     Document Type: Article

References (26)

1. Dellinger R.P., Carlet J.M., Masur H., Gerlach H., Calandra T., Cohen J., et al. Surviving sepsis campaign guidelines for the management of severe sepsis and septic shock. Crit Care Med 2004, 32:858-873.
2. Davis K.A. Ventilator-associated pneumonia: a review. J Intensive Care Med 2006, 21:211-226.
3. Juffermans N.P., Dekkers P.E., Verbon A., Speelman P., van Deventer S.J., van Der Poll T. Concurrent upregulation of urokinase plasminogen activator receptor and CD11b during tuberculosis and experimental endotoxemia. Infect Immun 2001, 69:5182-5185.
4. May A.E., Kanse S.M., Lund L.R., Gisler R.H., Imhof B.A., Preissner K.T. Urokinase receptor (CD87) regulates leukocyte recruitment via beta2 integrins in vivo. J Exp Med 1998, 188:1029-1037.
5. Connolly B.M., Choi E.Y., Gårdsvoll H., Bey A.L., Currie B.M., Chavakis T., et al. Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation. Blood 2010, 116:1593-1603.
6. Pliyev B.K., Menshikov M.Y. Release of the soluble urokinase-type plasminogen activator receptor (suPAR) by activated neutrophils in rheumatoid arthritis. Inflammation 2010, 33:1-19.
7. Ostrowski S.R., Piironen T., Hoyer-Hansen G., Gerstoft J., Pedersen B.K., Ullum H. High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005, 39:23-31.
8. Sidenius N., Sier C.F., Ullum H., Pedersen B.K., Lepri A.C., Blasi F., et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000, 96:4091-4095.
9. Henic' E., Borgfeldt C., Christensen I.J., Casslèn B., Høyer-Hansen G. Cleaved forms of the urokinase plasminogen activator receptor in plasma have Diagnostic Potential and predict Postoperative survival in patients with Ovarian Cancer. Clin Cancer Res 2008, 14:5785-5793.
10. Huttunen R., Syrjänen J., Vuento R., Hurme M., Huhtala H., Laine J., et al. Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 2011, 270:32-40.
11. Koch A., Voigt S., Kruschinski C., Sanson E., Duckers H., Horn A., et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 2011, 15:R63.
12. Giamarellos-Bourboulis E.J., Pechère J.C., Routsi C., Plachouras D., Kollias S., Raftogiannis M., et al. Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 2008, 46:1157-1164.
13. Baughman R.P. Diagnosis of ventilator-associated pneumonia. Curr Opin Crit Care 2003, 9:397-402.
14. Vincent J.L. Ventilator-associated pneumonia. J Hosp Infect 2004, 57:272-280.
15. Pugin J., Auckenthaler R., Mili N., Janssens J.P., Lew P.D., Suter P.M. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis 1991, 143:1121-1129.
16. Levy M., Fink M.P., Marshall J.C., Abraham E., Angus D., Cook D., et al. SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003, 31:1250-1256. 2001.
17. Riisbro R., ChristensenI J., Høgdall C., Brünner N., Høgdall E. Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers 2001, 16:233-239.
18. Kofoed K., Schneider U.V., Scheel T., Andersen O., Eugen-Olsen J. Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology. Clin Chem 2006, 52:1284-1293.
19. Pierrakos C., Vincent J.L. Sepsis biomarkers: a review. Crit Care 2010, 14:R15.
20. Georgopoulou A.P., Savva A., Giamarellos-Bourboulis E.J., Georgitsi M., Raftogiannis M., Antonakos N., et al. Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis. J Crit Care 2011, 26:331.e1-331.e7.
21. Kofoed K., Eugen-Olsen J., Petersen J., Larsen K., Andersen O. Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Eur J Microbiol Infect Dis 2008, 27:375-383.
22. Kofoed K., Andersen O., Kronborg G., Tvede M., Petersen J., Eugen-Olsen J., et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care 2007, 11:R38.
23. Rabna P., Andersen A., Wejse C., Oliveira I., Gomes V.F., Bonde-Haaland M., et al. Urine suPAR levels compared with plasma suPAR levels as predictors of post-consultation mortality risk among individuals assumed to be TB-negative: a prospective cohort study. Inflammation 2010, 33:374-380.
24. Rabna P., Andersen A., Wejse C., Oliveira I., Gomes V.F., Haaland M.B., et al. High mortality risk among individuals assumed to be TB negative can be predicted using a simple test. Trop Med Int Health 2009, 14:986-994.
25. Ostrowski S.R., Plomgaard P., Fischer C.P., Steensberg A.S., Møller K., Høyer-Hansen G., et al. Interleukin-6 infusion during human endotoxaemia inhibits in vitro release of the urokinase receptor from peripheral blood mononuclear cells. Scand J Immunol 2005, 61:197-206.
26. Shapiro N.I., Schuetz P., Yano K., Sorasaki M., Parikh S.M., Jones A.E., et al. The association of endothelial cell signaling, severity of illness, and organ dysfunction in sepsis. Crit Care 2010, 14:R182.